ASX ANNOUNCEMENT

17 November 2026

2026 Annual General Meeting – Addresses and Presentation

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) attaches in accordance with ASX Listing Rule 3.13.3, a copy of the addresses by Chair, Leigh Farrell and Managing Director and CEO, Brent Owens, and slides to be presented at today's Annual General Meeting.

ENDS

This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Adrian Mulcahy
Managing Principal, Automic Markets
adrian.mulcahy@automicgroup.com.au

Tim Sharpe
VP of Strategy & Corporate Development
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware (the Guardion) and LifeChain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.

Chair's Address

Opening and welcome

Good afternoon, ladies and gentlemen, and welcome to the 2026 Annual General Meeting of Vitrafy Life Sciences Limited. My name is Leigh Farrell, and it is my privilege to address you for the first time as your Chair.

I would like to welcome shareholders joining us here in Melbourne and online, as well as my fellow directors, our Managing Director and CEO Brent Owens, members of our executive team, our Company Secretary Michael Sapountzis, and representatives of our auditor, Grant Thornton.

Before we turn to the formal business of the meeting, I want to take a moment to reflect on the year, the board's priorities and where we are heading.

From Scientific Validation to Commercial Execution

A year ago, Vitrafy was an Australian-based company with a promising cryopreservation technology and early evidence of quality post-thaw outcomes. FY26 saw the transition from R&D to early commercialisation, with the pieces of our commercial business beginning to fall into place:

- Our independently validated scientific achievements have established credibility;
- Our growing partnerships demonstrate genuine industry interest;
- Our regulatory progress is creating a pathway to broader adoption; and
- Our transition to a U.S. centred operating model brings Vitrafy closer to the customers and markets we intend to serve.

Reflecting on the year's achievements, the turning point was our platelet study results with the U.S. Army Institute of Surgical Research released in May. Independent results from a highly credible partner gave the industry a reason to engage with us, and it did. The results firmly established Vitrafy as a viable option to meet the changing needs of the market and leading U.S. blood collection organisations are now evaluating our ecosystem as the cryopreservation solution of the future.

With a competitive advantage established in blood, two structural forces underpin the Board's confidence in the Company's ability to gain significant commercial adoption in the U.S. blood market:

- First, platelets have a shelf life measured in days, and there is currently no FDA-approved cryopreserved platelet product available in the United States.
- Second, the legacy technologies used to freeze red blood cells are reaching end of life and the industry is actively seeking a successor.

The structural forces at play represent significant tailwinds for Vitrafy in its approach to market but also catalysts for adoption of Vitrafy's cryopreservation technology.

These are not problems we need to persuade the market it has. These are problems the market is actively trying to solve; problems that Vitrafy's cryopreservation ecosystem can solve.

Matching the clear, actionable market need with the validated ecosystem outcomes was the basis for the strategic decision to concentrate our direct to market resources on human health in the U.S., while pursuing animal reproduction through our partnership with IMV Technologies, a global leader in that industry.

This strategy of how Vitrafy successfully commercialises our cryopreservation ecosystem is one cryopreservation ecosystem, addressing multiple industries, simultaneously building multiple pathways to recurring revenue – ultimately, delivering long-term shareholder value.

Capital and Discipline
Our approach is simple: every major investment is linked to a milestone to building shareholder value.

With realisation of several milestones across FY26, Vitrafy remains in an investment phase, deploying capital ahead of anticipated demand. In June, we completed a $30 million institutional placement, followed in July by the closing of a $2 million share purchase plan.

The capital we raised this year was specific, targeted and in-line with our strategic objectives: cryopreservation device scale up, U.S. manufacturing establishment and scaling up U.S. operations. We firmly believe this investment will drive value for our shareholders and will underpin our commercial scale-up over FY27 and beyond.

On behalf of the Board, I thank new and existing shareholders for that strong endorsement of our strategy and ongoing belief in the vision the Company has outlined.

As at 30 September, the Company held approximately $38.3 million in cash and term deposits. While costs in the short term will continue to rise as we invest in validation, manufacturing and the delivery of initial medical device units, the drive towards a commercial operation will drive value for our shareholders.

Board, leadership and governance
A strategy is only as strong as the people executing it. Over the past year, the Board has reshaped Vitrafy's leadership for the next phase.

Co-founder Brent Owens has completed his first year as Managing Director and CEO, succeeding Kate Munnings. I am pleased that Kate continues to contribute actively as a Non-Executive Director.

In January, we welcomed Dr Jeannette (Jeannie) Joughin to the Board. Jeannie brings more than three decades of senior executive and board experience in biotechnology and medical technology across the United States and Australia. Importantly, she has deep expertise in blood, blood products and cell and gene therapy. Jeannie chairs our Remuneration and Nomination Committee and is a member of the Audit and Risk Committee.

The executive team now matches our U.S. focus, with the recent appointment of a U.S.-based Chief Operating Officer and Chief Regulatory Officer alongside our Chief Commercial Officer and Chief Scientific Officer based in Colorado. Together, they bring deep industry expertise in the cryopreservation of blood products and cell and gene therapy. Brent will relocate to to build out our U.S. headquarters, and our new Scientific Advisory Board will guide our path to clinical adoption.

Jan Gielen will join as Chief Financial Officer on 1 February 2027. Jan joins from PolyNovo and has guided businesses from R&D to commercial medical device companies with operations in the United States.

It would be remiss not to acknowledge the foundations of this strategy established by our team in Ballarat. The work of the team to build the technology and approach that positions us so well in a significant global market cannot be underestimated. I thank them for their contributions.

Outlook

We are taking significant steps in building the organisation to execute our strategy in our target markets.

We see a clear pathway to a number of strategic milestones this year.

- Securing U.S. FDA listing for the Guardion in coming weeks will be a significant achievement and a key step in commercialising our technology.
- Scaling up supply of medical devices to meet current and anticipated demand will be critical to turning interest into market traction.
- Continuing to partner with leading participants across blood and cell and gene therapy will extend our reach into our target markets.
- Deploying our devices with those partners is ultimately the catalyst for converting evaluation trials into long-term, recurring revenue.

These achievements will build further value for shareholders and deliver a strong base for our commercial scale-up in the U.S, and ultimately globally.

On behalf of the Board, I thank Brent, the executive team and all our team in Australia and the United States for their dedication this year. I thank my fellow directors for their counsel and commitment. And I thank you, our shareholders, partners and collaborators, for your continued support.

I will now hand over to Brent for the CEO's address, after which we will move to formal business of the meeting.

Managing Director and CEO's Address

Thank you, Leigh. And good afternoon, everyone — here in the room and online.

Twelve months ago, at this meeting, we put our Guardion cryopreservation freezer on display and cryopreserved blood platelets live in front of you, in the time it takes to make a coffee. That introduced you to the promise of our approach to cryopreservation. Today, that promise is being realised, with the key commercial pillars falling into place.

2026 was the year Vitrafy moved from scientific validation to commercial execution:

- We went from zero Guardion devices to 19 — ten across FY26, and nine in the first quarter of this year alone.
- We went from no U.S. civilian blood partners to three, alongside the U.S. Army. That took us from 0% exposure to around 17% of U.S. blood collection sites.
- We went from conversations to contracts in cell and gene therapy, with our first U.S. agreement, with Charter Medical.
- We went from a domestic aquaculture service to an agreement with IMV Technologies, the global leader in animal reproduction — under the recurring revenue model we envisaged.
- We have a robust financial position to support growth, with $38.3 million in cash and term deposits as at the end of Q1 FY27.

A year ago, we had a promise. Today, we have devices, partners, customers and capital.

Today, I want to walk you through what we achieved across FY26 and how that is going to set the Company up for further success across FY27 and beyond.

Let's start with market development.

FY26 was about turning industry curiosity into signed partnerships — and we did that across all three of our priority markets.

We believe the Blood market is our biggest opportunity, with interest accelerating during the year due to the industry facing two structural problems that will compound the growing gap between Supply and Demand. Blood Platelets save life's, they are expensive, always in critical need but last only days on the shelf - expiration is high. There is no FDA-approved frozen platelet product on the market. At the same time, the legacy technology used to freeze red blood cells is reaching end of life, putting existing & future stockpiles at risk. Two urgent problems. We have built One platform that we believe can address both. We want to turn blood from 'on demand' to an 'inventory asset'.

The science opened these doors. In the U.S. Army's independent study using Vitrafy's technology, we delivered 94.4% mean post-thaw platelet recovery — much higher than the U.S. & other international guidelines. And our 'rapid response' protocol kept nearly twice the key clotting receptors when compared to existing methods. These in-vitro results are a positive step forward and got the industry's attention.

In FY26, we signed with Vitalant and Hoxworth. This quarter, Versiti joined them — across multiple blood products - red cells, platelets and plasma.

Having exposure to approximately 17% of the blood collection centers in the market provides a clear pathway for scale up as we successfully convert the partnerships to revenue generating contracts.

Whilst we see blood as our biggest opportunity, cryopreservation has widespread applications and we have made material progress across our other 2 priority areas, in cell & gene therapy and animal reproduction. In cell and gene therapy, Charter Medical is our first U.S. agreement. And in animal reproduction, IMV Technologies, the global leader, is already generating recurring revenue for us.

And we expect more partners to join this list in 2027.

So how does a partnership become convert from an unpaid partnership to commercial agreement? Many will follow the same three steps.

First, we partner — with industry leading and influential organisations. Second, we deploy Guardion and LifeChain on for our partners to evaluate the performance and suitability of our technology in their workflows, which is a requirement. And thirdly, upon success, we convert — to commercial adoption, with revenue recurring fees and clinical use. As we are a new technology to market, we see this order being consistent, but over time, commercial contracts should occur at an earlier stage.

Today, planning and deployment to Vitalant, Hoxworth, Versiti and Charter Medical are underway and in the Animal space, IMV are already paying and we are progressing to determine a joint technology offering for the global animal reproduction market.

Our strategy to attract and capture the market has proven too been effective and is highly scalable. Every device we place is designed to embed into the customer's workflow, creating a competitive moat that is difficult to breach.

To service this demand, we need our ecosystem in market.

We are on-track to have the Guardion listed by the FDA as a Class II medical device in the coming weeks. A large portion of our Verification & Validation testing is complete, and Plasma testing is well progressed with our partners.

I'm confident about successfully listing the Guardion for two reasons:

1. We have done it before with our generation 1 device; and
2. We have a very dedicated, experienced and motivated team who are executing to plan with established partners.

This is a well-trodden path for our team.

And it matters. Listing takes Guardion from research use into regulated human health settings — blood centres, hospitals and cell therapy manufacturing. It broadens who can buy from us.

We are close to achieving this FDA milestone. And the demand on the other side is already lining up.

Which brings me to the scale up of our fleet.

Our build rate has stepped up. We built ten Guardion devices across FY26. In the first quarter of this year alone, we built nine — almost a full year's output in a single quarter. We have six more forecast to be released this quarter, taking us to around 25 completed.

Right now, these research-use units are going to partners and into verification & validation testing. In early 2027, after FDA listing, we will have manufactured our first medical device fleet in Australia, building supply ahead of demand. U.S. manufacturing will follow, operational in the second half of calendar 2027.

We are moving from building devices to building a fleet.

To deliver our ecosystem, we have reoriented our team closer to our customers.

Our customers are in the United States, so that is where we are going. Colorado is our new U.S. base of operations, and I am relocating to lead it.

Over the last 12 months, we have bolstered our executive leadership, bringing on a team of highly credentialled and experienced operators to steer the next phase of growth: Tim Costello is our Chief Commercial Officer. Heather Pidcoke, our Chief Scientific Officer, brings deep expertise in regulated blood products for military and civilian use. We have also had two new additions with Pierre Emeric is our Chief Operating Officer and Tiffany Ramsey as our Chief Regulatory Officer. Five of our six executives are now based in the U.S.

A corporate function led by our CFO will remain in Australia.

As our operations move to Colorado, I want to recognise our Ballarat team. They helped build this technology. They took it from an idea in a small shed, to a fleet of solutions heading into America's blood centres to address critical lifesaving needs. Everything we do next stands on their shoulders. To that team: thank you.

We have also brought world-class scientific leadership around us.

Our Scientific Advisory Board brings together five independent advisers from leading U.S. and Canadian institutions: Folashade Otegbeye, Jose Cancelas, Pampee Young, Don Jenkins and Richard Cook. Between them, they cover transfusion medicine, cell and gene therapy, trauma care and biostatistics. True industry giants that have a proven track record of making positive change. Their role is to guide our scientific and clinical direction, and to help shape the studies we run with our partners. When leaders of this calibre put their names alongside Vitrafy, it tells you something about the science.

We have the right people, in the right place, at the right time.

None of this happens without the ongoing support and trust of our shareholders.

In June and July, we raised $32 million — a $30 million placement at $2.60, and a $2 million share purchase plan. Demand well exceeded what we sought. To our existing shareholders who backed us again, and to the new investors who joined us: thank you.

This raise was critical to maintain the momentum we had generated across the first half of FY26 and ensure we were well capitalised to invest in our fleet of devices ahead of time.

As a result, we are in a strong financial position and now have the financial footing to accelerate our growth. We finished September with $38.3 million in cash and term deposits — around 7.9 quarters of funding at our first-quarter net operating outflow of $4.9 million. We are also exploring non-dilutive funding options.

Our spending is focused on four priorities: validation, manufacturing, U.S. commercial operations and talent. Every dollar is pointed at one goal — turning proven science into recurring revenue.

Which brings me to our objectives for FY27.

Last year, we set three objectives: market development, products in market and organisational capability. We delivered on them. This year, they move forward.

Convert — turning partner evaluations into commercial adoption and recurring revenue.
Scale — growing device supply and securing Guardion's medical device listing.
Build — establishing our U.S. organisation and operations, with Colorado as our base.

And underpinning all of it: quality and consistency in everything we do.

A year ago, we showed you what Vitrafy could do with our first Guardion prototype being revealed. This year, we've proved it. Now, we grow it.

We have the technology. We have the partners. And we have a team that delivers. The most exciting part starts now.

To our team in Australia and the U.S., to our Board, and to every one of you who has backed this company: thank you.

I'll now hand back to Leigh.

Vitrafy Life Sciences

Pioneering Technology, *Preserving Life.*

Annual General Meeting

17 November 2026

INTRODUCTION

Vitrafy Board of Directors



Dr Leigh Farrell

Non-Executive Chair



Brent Owens

Managing Director and CEO



Kate Munnings

Non-Executive Director



Dr Jeannette Joughin

Non-Executive Director



Vaughan Webber

Non-Executive Director

vitrafy LIFE SCIENCES

AGENDA

Format of Meeting

1. Chair Address
2. CEO Address
3. Questions and Voting
4. Formal Business of the Meeting
5. General Questions
6. Meeting Close

vitrafy LIFE SCIENCES

Chair Address

vitrafy LIFE SCIENCES

CEO ADDRESS

From promise to execution.

AGM 2025

Twelve months ago, a promise.

The first Guardion prototype cryopreserved platelets live on stage — in the time it takes to make a coffee.



Overview

Last year's commitments to shareholders. Three objectives, all three delivered.

1

Market Development

- Blood: Vitalant, Hoxworth and Versiti
- Cell & gene therapy: Charter Medical
- Animal reproduction: IMV Technologies

Delivered

2

Products in Market

- 19 Guardion devices built
- FDA listing close

Delivered

3

Organisational Capability

- U.S. leadership team in place
- Colorado base in place

Delivered

vitrafy LIFE SCIENCES

Highlights

We delivered on our commitments for FY2026 delivering devices, partners, customers and capital.

0	**19**	Guardion devices built
0	**3**	U.S. civilian blood partners, plus the U.S. Army
Conversations	**Contracts**	First U.S. cell & gene therapy agreement — Charter Medical
Aquaculture service	**IMV agreement**	Global leader in animal reproduction — recurring revenue
Capital Raise	**$38.3m**	Cash and term deposits at the end of Q1 FY27

vitrafy LIFE SCIENCES

Market Development

Great progress in FY26 converting industry curiosity into partnerships across our priority application areas.

Blood and blood products

vitalant Innovation Center

Red blood cells

Hoxworth Blood Center, University of Cincinnati

Red blood cells

versiti

Platelets and plasma

United States Army Institute of Surgical Research

Platelets

Cell and gene therapy

CharterMedical

First U.S. cell and gene therapy agreement

Animal reproduction

imv TECHNOLOGIES

Global leader in animal reproduction

More partners expected to join early in 2027

Market Development

Partnerships follows a consistent path from agreement to recurring revenue.

1

Partner

Agreements with leading blood, cell and gene therapy and animal health organisations

2

Integration

Deploy Vitrafy technology for partner validation in their own workflows prior to clinical use

3

Convert

Commercial adoption with recurring revenue and clinical use

vitrafy LIFE SCIENCES

Product Development: FDA Listing

Guardion listing as a Class II medical device expected in the coming weeks.

Complete
Gen 1 device & GUARDION builds

Well progressed
Verification & Validation

Well progressed
Plasma testing commenced

Next
Guardion Class II listing

De-risking
Gen 1 device learnings applied to GUARDION FDA process

Experienced Partners
Executing to plan with established partners

Experienced Team
Experienced Executive leadership strengthens capability

FDA

vitrafy LIFE SCIENCES

Product Development

Scaling device supply ahead of demand, then moving manufacturing to the U.S.

Guardion device builds



Supply roadmap

Now

Research-use units

Deployed with partners and for verification testing.

Early 2027

First medical device fleet

Additional manufactured devices in Australia following FDA listing to build supply for anticipated demand.

2H CY2027

U.S. manufacturing

Operational in the second half of calendar 2027, updated from 1H FY27.

vitrafy LIFE SCIENCES

Organisational Capability

A U.S.-centred leadership team, with Colorado as our new base of operations.

Executive Team



Brent Owens
Chief Executive Officer



Simon Martin
Chief Financial Officer



Tim Costello
Chief Commercial Officer



Heather Pidcoke
Chief Scientific Officer



Pierre Emeric
Chief Operating Officer



Tiffany Ramsey
Chief Regulatory Officer

U.S.-based Australia-based

U.S. Base of Operations: Colorado



Note: Jan Gielen will commence as CFO on 1 February 2027

Scientific Leadership for Our Next Phase

Deep expertise and industry leadership across blood, cell therapy and trauma care.

Scientific Advisory Board



Transfusion medicine

Pampee Young

MD, PhD

American Red Cross



Cell therapy

Jose Cancelas

MD, PhD

Dana-Farber Cancer Institute



Cell & gene therapy

Folashade Otegbeye

MD, MPH

Fred Hutch Cancer Center



Trauma care

Don Jenkins

MD

UT Health San Antonio



Biostatistics

Richard Cook

PhD

University of Waterloo

vitrafy LIFE SCIENCES

Funding the Next Stage

Funding supports device manufacturing and the expansion of U.S. operations.

Funding

$32m

- $30m placement at $2.60 in June 2026
- $2m share purchase plan in July 2026
- Non-dilutive funding options being explored

Cash Position

$38.3m

- Cash and term deposits at 30 September 2026
- ~7.9 quarters of funding at the Q1 FY27 net operating outflow of $4.9m

vitrafy LIFE SCIENCES

Outlook: Convert. Scale. Build.

Convert

Partner evaluations into commercial adoption and revenue

Recurring Revenue

Scale

Grow device supply and secure Guardion’ s medical device listing

Device fleet: early 2027

Build

U.S. organisation and operations, with Colorado as our base

U.S. manufacturing: H2 CY2027

Underpinned by quality and consistency in everything we do.

A YEAR AGO, WE SHOWED YOU WHAT GUARDION COULD DO. THIS YEAR, WE PROVED IT.

The technology.
The partners.
The funding.
The team.

The most exciting part starts now.

Q&A / Voting Procedure Overview

vitrafy LIFE SCIENCES

MEETING PROCEDURE

Q&A / Voting Procedure Overview

Online Attendees – Question Process

1. To ask a written question select the Q & A icon

2. Type your question in the text box and press the send button

vitrafy LIFE SCIENCES

MEETING PROCEDURE

Q&A / Voting Procedure Overview

Online Attendees - Voting Procedure

1. When the poll is open, sign in and click “Go to voting”
2. To vote, select either For, Against or Abstain
3. You will see a vote confirmation
4. To change your vote, click “Go to voting” at any time until the poll is closed

vitrafy LIFE SCIENCES

Formal Business of the Meeting

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Financial Statements and Reports

Ordinary business

> *To receive and consider the Company's Financial Statements, Directors' Report and Auditor's Report for the financial year ended 30 June 2026.*

Further Information

- Simon Martin, Chief Financial Officer of Vitrafy and Tim Jackman, Audit Partner from Grant Thornton, the Company's external Auditor are present and available to answer any queries.
- Please note there is no requirement for a resolution in relation to the receipt and consideration of Accounts and Reports.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 1 – Adoption of Remuneration Report

To consider and, if thought fit, to pass the following resolution as a non-binding ordinary resolution:

> *"That, for the purpose of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's Annual Report for the year ended 30 June 2026."*

FOR	AGAINST	OPEN	ABSTAIN
8,575,583 99.97%	805 0.01%	2,000 0.02%	–

Further Information

- Voting restrictions apply to Resolution 1.
- The vote on this Resolution is advisory only and does not bind the Directors or Company.
- Noting that each Director has a personal interest in their own remuneration, the Board recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 2 – Election of Jeannette Joughin as a Director

To consider and, if thought fit, pass as an ordinary resolution:

> *"That, Jeannette Joughin, who was appointed as an addition to the Board since the last Annual General Meeting of the Company and who retires in accordance with clause 63.2 of the Company's Constitution and, being eligible, offers herself for election, be elected as a Director of the Company."*

FOR	AGAINST	OPEN	ABSTAIN
8,963,357 99.98%	0 0.00%	2,000 0.02%	–

Further Information

- The Board (with Jeannette Joughin abstaining) recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 3 – Re-election of Kate Munnings as a Director

To consider and, if thought fit, pass as an ordinary resolution:

> *"That, Kate Munnings, a Director of the Company who retires in accordance with clause 64.1 of the Company's Constitution and, being eligible, offers herself for re-election, be re-elected as a Director of the Company."*

FOR	AGAINST	OPEN	ABSTAIN
6,136,893 99.97%	0 0.00%	2,000 0.02%	2,826,464

Further Information

- The Board (with Kate Munnings abstaining) recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 4 – Grant of Performance Rights to Managing Director and CEO, Brent Owens

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

> *"That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the grant of 287,490 Performance Rights to Brent Owens, a Director of the Company (or his nominee) under the Company's EIP (including the issue of Shares on the vesting and exercise of those Performance Rights) in accordance with the terms set out in the Explanatory Statement."*

FOR	AGAINST	OPEN	ABSTAIN
8,958,472 99.92%	4,885 0.05%	2,000 0.02%	–

Further Information

- Voting restrictions apply to Resolution 4.
- The Board (with Brent Owens abstaining) recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 5 – Ratification of Prior Issue of Placement Shares

To consider and, if thought fit, pass the following resolution as an ordinary resolution:

> *"That, under and for the purposes of Listing Rule 7.4 and for all other purposes, the prior issue of 11,538,462 fully paid ordinary shares as described in the Explanatory Statement is ratified and approved."*

FOR	AGAINST	OPEN	ABSTAIN
4,813,209 97.28%	132,410 2.68%	2,000 0.04%	–

Further Information

- Voting restrictions apply to Resolution 5.
- The Board recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution.

vitrafy LIFE SCIENCES

FORMAL BUSINESS

Resolution 6 – Approval of 10% Placement Facility

To consider and, if thought fit, pass the following resolution as a special resolution:

> *"That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement."*

FOR	AGAINST	OPEN	ABSTAIN
8,452,101 94.28%	511,256 5.70%	2,000 0.02%	–

Further Information

- Voting restrictions apply to Resolution 6.
- The Board recommends that Shareholders vote in FAVOUR of this Resolution.
- The Chair of the Meeting intends to vote undirected proxies in FAVOUR of this Resolution

vitrafy LIFE SCIENCES

General Questions

vitrafy LIFE SCIENCES

Voting Closure and End of Formal Business

vitrafy LIFE SCIENCES

Thank you

Pioneering Technology, *Preserving Life.*

Vitrafy Life Sciences Limited

vitrafy.com